Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Context: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2018-01-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | http://www.endocrineconnections.com/content/7/1/115.full |
| _version_ | 1818260400803676160 |
|---|---|
| author | Signe Frøssing Malin Nylander Caroline Kistorp Sven O Skouby Jens Faber |
| author_facet | Signe Frøssing Malin Nylander Caroline Kistorp Sven O Skouby Jens Faber |
| author_sort | Signe Frøssing |
| collection | DOAJ |
| description | Context: Women with polycystic ovary syndrome (PCOS) have an increased risk of
cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical
CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic
peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate
system controlling fluid and hemodynamic homeostasis through vascular tonus and
diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2
diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a
decrease in particular MR-proANP.
Objective: To investigate if treatment with liraglutide in women with PCOS reduces
levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin.
Methods: Seventy-two overweight women with PCOS were treated with 1.8 mg/
day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers,
anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were
examined.
Results: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45–0.56) nmol/L,
MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean
percentage differences (95% CI) between liraglutide and placebo group after treatment
were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11,
P = 0.001) and copeptin +4% (−13 to 25, P = 0.64). Reduction in MR-proANP concentration
correlated with both increased heart rate and diastolic blood pressure in the liraglutide
group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin
resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be
independently correlated with an increase in the heart rate.
Conclusion: In an RCT, liraglutide treatment in women with PCOS reduced levels of
the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6%
(borderline significance) compared with placebo. The decrease in MR-proANP was
independently associated with an increase in the heart rate. |
| first_indexed | 2024-12-12T18:30:44Z |
| format | Article |
| id | doaj.art-a73dfea82d35446e94768d874e4168af |
| institution | Directory Open Access Journal |
| issn | 2049-3614 2049-3614 |
| language | English |
| last_indexed | 2024-12-12T18:30:44Z |
| publishDate | 2018-01-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-a73dfea82d35446e94768d874e4168af2022-12-22T00:15:55ZengBioscientificaEndocrine Connections2049-36142049-36142018-01-017111512310.1530/EC-17-0327Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOSSigne Frøssing0Malin Nylander1Caroline Kistorp2Sven O Skouby3Jens Faber4Department of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, DenmarkDepartment of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark; Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, DenmarkDepartment of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, DenmarkDepartment of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark; Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, DenmarkDepartment of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, DenmarkContext: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate system controlling fluid and hemodynamic homeostasis through vascular tonus and diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a decrease in particular MR-proANP. Objective: To investigate if treatment with liraglutide in women with PCOS reduces levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin. Methods: Seventy-two overweight women with PCOS were treated with 1.8 mg/ day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers, anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were examined. Results: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45–0.56) nmol/L, MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64). Reduction in MR-proANP concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be independently correlated with an increase in the heart rate. Conclusion: In an RCT, liraglutide treatment in women with PCOS reduced levels of the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6% (borderline significance) compared with placebo. The decrease in MR-proANP was independently associated with an increase in the heart rate.http://www.endocrineconnections.com/content/7/1/115.fullPCOSatrial natriuretic peptideadrenomedullincopeptinGLP-1 receptor agonist |
| spellingShingle | Signe Frøssing Malin Nylander Caroline Kistorp Sven O Skouby Jens Faber Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS Endocrine Connections PCOS atrial natriuretic peptide adrenomedullin copeptin GLP-1 receptor agonist |
| title | Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS |
| title_full | Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS |
| title_fullStr | Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS |
| title_full_unstemmed | Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS |
| title_short | Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS |
| title_sort | effect of liraglutide on atrial natriuretic peptide adrenomedullin and copeptin in pcos |
| topic | PCOS atrial natriuretic peptide adrenomedullin copeptin GLP-1 receptor agonist |
| url | http://www.endocrineconnections.com/content/7/1/115.full |
| work_keys_str_mv | AT signefrøssing effectofliraglutideonatrialnatriureticpeptideadrenomedullinandcopeptininpcos AT malinnylander effectofliraglutideonatrialnatriureticpeptideadrenomedullinandcopeptininpcos AT carolinekistorp effectofliraglutideonatrialnatriureticpeptideadrenomedullinandcopeptininpcos AT svenoskouby effectofliraglutideonatrialnatriureticpeptideadrenomedullinandcopeptininpcos AT jensfaber effectofliraglutideonatrialnatriureticpeptideadrenomedullinandcopeptininpcos |